Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared Wi

Indication
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Bladder (Urothelial, Transitional Cell) Cancer; Non-Muscle Invasive Bladder Carcinoma

Other upcoming events for TARA

Phase 3 ReadoutPhase 3 Topline: A Phase 2b/3 Randomized Open-Label Dose-Selection Study With Open-Label Extension and Randomized Dou
Patent ExpiryPatent/Exclusivity Expiry: VYKAT XR
Patent ExpiryPatent/Exclusivity Expiry: ALVAIZ
Patent ExpiryPatent/Exclusivity Expiry: SUCCINYLCHOLINE CHLORIDE

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Intravesical TARA-002 Compared Wi — TARA Phase 3 Readout | BioSniper